Rapid Acting insulin with pre-treatment of rHuPH20
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes Mellitus
Conditions
Type 1 Diabetes Mellitus
Trial Timeline
Oct 3, 2013 → Feb 27, 2014
NCT ID
NCT03662334About Rapid Acting insulin with pre-treatment of rHuPH20
Rapid Acting insulin with pre-treatment of rHuPH20 is a approved stage product being developed by Halozyme Therapeutics for Type 1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT03662334. Target conditions include Type 1 Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type 1 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03662334 | Approved | Completed |
Competing Products
20 competing products in Type 1 Diabetes Mellitus